drugset / Trial / NCT03651219
Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of the study is to evaluate the safety and efficacy of apatinib mesylate tablets and chemotherapy drug Irinotecan in treatment of recurrent SCLC stage IIIB\&IV patients. It is a randomized controlled clinical trial.
Timeline
- Start
- 2018-09-08
- Primary completion
- 2019-08-08
- Completion
- 2020-08-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 80 mg/m2 | Intravenous |
| Subject | Rivoceranib | Small molecule | 250 mg | Oral |